Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HINT1 | P49773 | 5/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 2/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26515 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL3713950 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL18512866 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12031119 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12150640 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL222316 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL12300426 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16360143 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL16198946 | 1.00 | HPGD (0.61) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| Water SCHEMBL25345533 | 0.99 | HPGD (0.60) | HPGDHINT1NT5ETAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| EP-2120566-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008082601-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1525209-A2 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |